Gracell Biotechnologies Stock Revenue
Gracell Biotechnologies fundamentals help investors to digest information that contributes to Gracell Biotechnologies' financial success or failures. It also enables traders to predict the movement of Gracell Stock. The fundamental analysis module provides a way to measure Gracell Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gracell Biotechnologies stock.
Gracell |
Gracell Biotechnologies Company Revenue Analysis
Gracell Biotechnologies' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Gracell Biotechnologies reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Gracell Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gracell Biotechnologies' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics of similar companies.Gracell Biotechnologies is currently under evaluation in revenue category among its peers.
Gracell Fundamentals
| Return On Equity | -0.32 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 96.57 M | |||
| Shares Owned By Insiders | 16.39 % | |||
| Shares Owned By Institutions | 63.11 % | |||
| Number Of Shares Shorted | 1.19 M | |||
| Price To Book | 4.39 X | |||
| Price To Sales | 732.21 X | |||
| Gross Profit | 366 K | |||
| EBITDA | (509.64 M) | |||
| Net Income | (496.98 M) | |||
| Cash And Equivalents | 1.71 B | |||
| Cash Per Share | 25.28 X | |||
| Total Debt | 182.98 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 8.01 X | |||
| Book Value Per Share | 16.90 X | |||
| Cash Flow From Operations | (482.65 M) | |||
| Short Ratio | 0.87 X | |||
| Earnings Per Share | (0.97) X | |||
| Target Price | 10.58 | |||
| Number Of Employees | 314 | |||
| Beta | -0.34 | |||
| Market Capitalization | 989.87 M | |||
| Total Asset | 1.66 B | |||
| Retained Earnings | (1.63 B) | |||
| Working Capital | 1.28 B | |||
| Z Score | 1.78 | |||
| Net Asset | 1.66 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |